A.P. Pharma, Inc.

A.P. Pharma, Inc.

A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company focused on developing pharmaceutical products using its Biochronomer polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, which completed a pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting (CINV) during the year ended December 31, 2008. APF530 is designed to prevent CINV for at least five days and contains granisetron, a drug approved for the prevention of CINV. In addition to its lead drug candidate, A.P. Pharma has a pipeline of other product candidates that use its Biochronomer technology. One of these, APF112, incorporates the local anesthetic, mepivacaine. It is designed to provide up to 36 hours of post-surgical pain relief and to minimize the use of morphine-like drugs, or opiates, which are used in post-surgical pain management.

Contact Details

Office Address

A.P. Pharma, Inc.
123 Saginaw Drive
Redwood City, CA, USA 94063
Phone: (650) 366-2626
Fax: (650) 365-6490

Executives

Chief Exec. Officer

Mr. Ronald J. Prentki

Sr. VP of R&D

Mr. John Barr

Business Reviews for A.P. Pharma, Inc.

Related Companies